Gen Li, PhD, MBA

The oncogene KRAS is one of the most prolific mutations in non-small cell lung cancer (NSCLC).

 Treatment of NSCLC patients with KRAS mutations has been so far unsuccessful, leading to this patient group being dubbed as untreatable.

There are various Codon 12 mutations seen in NSCLC KRAS patients. The top 4 variants are G12C, G12D, G12V and G12A, with G12C being the most common in this patient group.

The objective of this contextualized analysis is to construct a digital twin on NSCLC KRAS G12C patients with Standard of Care (SCA), as measured by median Progression-Free Survival (mPFS). In this analysis, a digital twin is defined as a typical demographic patient profile in a specific population; importantly the associated clinical outcomes with this cohort may help in the design of clinical trials.

Analysis was conducted using the Phesi Clinical Development Platform. At the time of analysis, this platform had data from 462,538 NSCLC patients enrolled in clinical trials.

The data were gathered based on a set of artificial intelligence and big data technology methods, ensuring data were indiscriminately gathered from existing digital sources, including anonymized patient data from existing clinical trial participant records. While statistical outliers possibly exist, conclusions were drawn from multiple and diversified data sources to minimize potential bias.

We identified patients with specific inclusion/exclusion criteria. Briefly, we included patients aged 18 years or older with histologically or cytologically confirmed, locally-advanced, or metastatic NSCLC (stage IIIB–IV), after failure of first line treatment. All patients had to have a confirmed KRAS mutation. Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. We also used the Progression Free Survival (PFS) as an outcome measure for those patients who met the inclusion/exclusion criteria.

In total, we identified 1,298 NSCLC patients with the KRAS mutation from 15 cohorts. These were predominantly in Phase II clinical trials.

A digital twin depicting the baseline patient characteristics is presented below:

Phesi Synthesized Patient Profile is a summarized table of a database, which includes details in each of the categories of data available for further analysis. Typically, it includes simple demographics, medication history, comorbidity, laboratory results, various disease measures, etc.

Patients in these 15 trials were predominantly white (92%), with ECOG performance status of 0 or 1 (96%) and failed first line treatment (76%).

There are 310 patients from 7 cohorts with detailed Codon 12 composition data:

Of these, 150 (48%) of them have G12C mutation. These data are consistent with reports that G12C is the most important variant in KRAS mutated patients.

To evaluate the PFS associated with this digital twin demographic profile, data from 1,100 NSCLC KRAS patients were available from 14 cohorts in Phase II clinical trials.

 These patients were recruited and treated from 1,077 investigator sites from 41 countries between March 2008 and April 2021. These clinical trials were sponsored by Bayer,

In this primary outcome digital twin, a simple linear distribution model demonstrated an estimated mPFS of 3.0 months, with a range of between 1.4 and 5.9 months.

In three cohorts, colored in blue, docetaxel was used as the active control. The mPFS for these groups were 2.6 months,

In one cohort, all 19 patients had G12C mutations. The mPFS for for this group was 3.3 months.

Separately, in a retrospective analysis of 69 G12C mutated patients treated by immune checkpoint inhibitors (ICIs), the mPFS was 3.09 months,

 similar to the other 14 cohorts analyzed. From the same analysis, all other patients with G12 codon mutations demonstrated similar mPFS following ICI treatments, with survival ranging between 2.66 months and 3.91 months.

The PFS data in ICI-treated KRAS mutated patients was comparable to that of the non-ICI KRAS cohorts.

From this analysis, various treatments, including the newly introduced immune checkpoint inhibitors, have a similar distribution of mPFS in a narrow band of two to four months among KRAS mutated NSCLC patients. Around half (48%) of these KRAS mutated patients had the G12C mutation. In a specific example of analysis,

 all four major Codon 12 variants consistently fell into the same two-month band, between 2.66 and 3.91 months. This leads us to conclude that a population of NSCLC patients with KRAS G12C mutation would yield a mPFS of about 3.0 months, when treated with Standard of Care (SOC).

This analysis suggests that a digital twin patient profile and its associated clinical outcome may be useful in the design of a prospectively recruited G12C patient population, when applying the same inclusion/exclusion criteria. The inclusion/exclusion criteria can be modified in what-if scenarios to see what effect it would have on PFS in each scenario.

The safety outcomes generated by the digital twin of primary efficacy outcomes in NSCLC patients with KRAS G12C mutation along with a digital twin demonstrating baseline patient characteristics for the same population could constitute a Synthetic Control Arm (SCA) in a prospectively planned and implemented single arm clinical trial.

This analysis was conducted in May 2021, before Amgen published its sotorasib results.

 The 6.8 months mPFS results of the sotorasib trial with a single arm design was more than double what was seen in this digital twin. We hope this predictive analysis will also be corroborated by several ongoing trials, using various SOC arms.

In the appropriate circumstances, for example with a sufficiently robust and well documented standard of care population, an SCA may increase the efficiency of clinical trials and address patient concerns about receiving placebo treatment in clinical trials.

This analysis does not include any data published after May 2021.

The approach discussed here should not be confused with the usual meta-analyses of multiple entire arms from multiple comparable trials. In contrast to that approach, the Phesi approach is to leverage AI to find, evaluate, and consolidate subpopulations of interest, to characterize their demographics and clinical outcomes. These what-if scenarios, depending on the subpopulations chosen, allow trialists to learn from previous trials and consider targeted subpopulations in their design and scoping of future clinical trials.

We need to indicate that while we have provided a detailed list of references, not all the details in this article can be found in these references, as some of those were extracted and synthesized from various sources through artificial intelligence.

, Chief Operations Officer; all with Phesi

Anna Biernacka, et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma Cancer Genet. 2016 May;209(5):195-8.

Ferdinandos Skoulidis, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation N Engl J Med. 2021 Jun 24;384(25):2371-2381.

Pasi A Jänne, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol. 2013 Jan;14(1):38-47.

Arnaud Jeanson, et al. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC) J Thorac Oncol. 2019 Jun;14(6):1095-1101.

Anne-Marie C Dingemans, et al. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation Clin Cancer Res. 2013 Feb 1;19(3):743-51.

Ji-Youn Han, et al. Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer Cancer Chemother Pharmacol. 2015 Mar;75(3):475-83.

E Rulli, et al. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial Ann Oncol. 2015 Oct;26(10):2079-84.

David E Gerber, et al. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer Lung Cancer. 2018 Mar;117:44-49.

Pasi A Jänne, et al. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial JAMA. 2017 May 9;317(18):1844-1853.

https://clinicaltrials.gov/ct2/show/results/NCT02642042?view=results

G R Blumenschein Jr, et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) Ann Oncol. 2015 May;26(5):894-901.

Suresh S Ramalingam, et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial Lancet Oncol. 2014 Nov;15(12):1369-78.

Ji-lin Guan, et al. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy Ann Surg Oncol. 2013 Apr;20(4):1381-8.

M C Pietanza, et al. Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas J Thorac Oncol. 2016 Jun;11(6):890-9.

Articles

Digital twins, defined as a typical demographic patient profile in a specific population, have the potential to help clinical trial design.

A Digital Twin on KRAS G12C NSCLC Patients with SCA Measured by PFS

Rigorously designed and implemented clinical trials are at the core of delivering innovative medicines to patients, and they have been especially important when developing COVID-19 vaccines and treatments. While our understanding of medicines has progressed enormously in the past 100 years, based on the lessons we have learned from clinical trials that have been conducted, the way we design and implement clinical trials remains quite primitive.

Our analysis of 330,000 clinical trials, the majority planned and implemented in the past 15 years, make it clear that there is no such thing as a perfectly designed protocol. This clinical trial database has been built through a combination of artificial intelligence and human intelligence with data dynamically extracted and tabulated from over 80,000 sources. One third of all trials can benefit from minor edits, while another third require significant improvement, as evidenced by numerous implemented amendments. For the remaining third, they often struggle from the get-go, are prone to enrollment challenges, require many amendments, and can often be on the brink of failure. As a matter of fact, most of the final third of trials do fail.

Unfortunately, various flaws in a clinical trial design are not immediately obvious at the planning stage and when writing the protocol. Even at the stage when we need to amend a protocol, the problem in a trial design is still heavily disguised as an operational challenge, such as enrollment challenge caused by poor investigator site selection.

Many corrections to the original protocol design are not complicated. Common protocol amendments are associated with inclusion and exclusion criteria, such as age, gender, disease stages and severity. Other amendments can be more complicated and can negatively impact the operational deliverability of the study, such as selection of primary end points.

As an example, Phesi has analyzed a particular multiple sclerosis trial (NCT00355134)

 that was originally designed to include only female patients. This may appear logical as multiple sclerosis is a disease more prominent in women. However, when analyzing 29,070 patients from 91 multiple sclerosis clinical trial arms from our synthetic patient profile database, there were 66.65% women and 33.35% men, a 2:1 ratio. When the clinical trial faced operational issues, with classic linear thinking, the trial design team added 25% more investigator sites, hoping to compensate for the smaller patient population, but still achieve a similar enrollment cycle time as a multiple sclerosis trial including both genders. Even though the protocol was further amended to include both male and female patients, the enrollment cycle time was significantly longer, and the resultant patient population deviated from the general patient population of the 3:1 ratio (844 women among 1083 randomized patients (78%)), which potentially jeopardizes any medical conclusion from the trial.

When analyzing recent Phase III multiple sclerosis trials from a statistical point of view, the most dominant value in gender inclusion for this type of trial is to include both men and women. This is the modal design value—a statistical concept, which simply means ‘the most frequently used’ value in other similar clinical trials.

 In this example, shown below, just three trials out of 168 were designed to only include female patients, and of those, two ended up including both genders through protocol amendments.

Preemptive and extensive protocol design analysis conclusively shows that a clinical trial design should start from industry modal values. Let us use another multiple sclerosis clinical trial to demonstrate the power of applying modal value-based design analysis in clinical protocol design. NCT00245622 was a Phase II trial designed to evaluate Autologous T Cell Vaccine (TCV) for multiple sclerosis—undoubtedly an innovative approach in this condition’s therapy. It is not uncommon to test various innovative ideas in designing a protocol with an exciting and innovative clinical development candidate. In its original design, amongst others NCT00245622

 included the following key inclusion criteria:

Diagnosis of MS within the past three years according to the McDonald criteria (2001).

Baseline Expanded Disability Status Scale (EDSS) score between 0 and 3.5 inclusively.

In analyzing 233 Phase II MS clinical trials, Phesi detects that these trial design components significantly differ from the industry modal values.

For patient age, shown below, the modal value is 18 to 55 years old. NCT00245622 was the only analyzed trial to include patients aged 18 to 45 years.

For Expanded Disability Status Scale (EDSS), shown below, the modal value is between 0 and 5.5. An EDSS score of 0 to 3.5 in trial NCT00245622 is a notable deviation from the modal value of 0 to 5.5.

Instead of using modal values to guide protocol design, and to identify and mitigate the risk at the planning and design stage, this clinical trial team learned the lesson the hard way. After a series of protocol amendments over a 12-month period, shown below, the trial design finally came back to modal values. However, this was only after losing time and enrollment momentum, incurring significant financial costs to the study team and their stakeholders.

A planned clinical trial doesn’t have to be restricted to use industry modal values. But this integrated clinical data science approach gives the study team the opportunity to challenge why a particular value outside of modal value has been adopted. If the team is proactively aware that they are designing outside of the modal values, they can objectively and often quantitatively assess the operational risks and other associated risks with the approach. This predictive analytical approach has tremendous benefits but clearly requires a significant data pool to increase confidence. It also requires an applied combination of artificial intelligence, machine learning, natural language processing, and integrated algorithms, to extract meaning from data sets.

While we use patient eligibility as an example here, a meaningful modal value guided protocol design requires a comprehensive analysis of all protocol design elements in a structured way. This includes primary and secondary outcome measure(s), treatment duration, comparators, and so on.

Modal value guided trial design cannot be conducted in a vacuum. An optimized trial design would have the best chance of coming from an integrated approach by examining the target patient population characteristics and other variables. It will certainly benefit from understanding how different design modifications can impact the operational implementation feasibility through a detailed Gross Site Enrolment Rate (GSER) analysis.

Peter A Calabresi, et al., Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled, Phase III trial Lancet Neurol. 2014 Jun;13(6):545-56.

Gen Li, METHOD AND SYSTEM FOR DEVELOPING CLINICAL TRIAL PROTOCOLS, International Patent Publication No. WO2020033754, published February 13, 2020.

Edward Fox, et al. A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design. Mult Scler. 2012 Jun;18(6):843-52.

Analysis of 330,000 clinical trials calls for improved protocol design process.

Modal Value Guided Clinical Trial Design Effectively Reduces Protocol Amendments

Analysis from virtual clinical development specialist Phesi shows the enrollment and effectiveness of two current COVID-19 vaccine trials conducted by global pharmaceutical development companies. On the surface, both trials appear to be on track to complete enrollment, however, looking deeper, there is a significant difference in the Site Effectiveness Index (SEI) between the two, with trial A scoring 84 percent and trial B scoring 39 percent. SEI is a metric to measure how effectively a clinical trial site activation process is executed.

Trial A completed enrollment on October 22, 2020, with 30,000 subjects, activating 99 sites in three months. After adjustment for site activation, each site enrolled 4.15 subjects per day. Trial B has activated 149 sites by October 22nd, 2020 but has been recruiting for over five and a half months.

Dr. Gen Li, President of Phesi, commented, “We estimate that it will take 175 sites to be activated and six months for Trial B to enroll its target of 43,998 subjects. If we make the same site activation adjustment (SEI 42 percent) it would enroll 3.75 subjects per day, significantly lower than Trial A.”

“This difference contributes significantly to the disparity in the observed SEI levels between the two trials, but another contributing factor is that Trial B has implemented a number of protocol amendments. Making protocol amendments is a known factor in many trials exceeding their projected timeframe and budget,” said Dr Li.

The amendments to Trial B included reducing the restrictions on the age of subjects and altering the target number to enroll from 8640 patients, to 7600, then 32,000, then 29,481. It now targets to enroll 43,998 subjects. Trial B also has an adaptive trial design, which should theoretically lead to an overall shorter development cycle, bringing the vaccine to patients faster – but often at the expense of higher financial costs.

“The data from the two trials show that in the hunt for a COVID-19 vaccine, there is varying success in activating investigator sites and enrolling patients, which must be tackled to accelerate development,” continued Dr Li. “In this comparison, the difference of enrollment cycle times between the two trials is three months vs. six months – a considerable time period in a global pandemic. Bringing innovative and life-saving medicines to patients is complicated and capital intensive. The solution to improving SEI and accelerating development requires a deep understanding of real-time, dynamically refreshed data and a forensic examination of the

Analysis from Phesi shows the enrollment and effectiveness of two current COVID-19 vaccine trials conducted by global pharmaceutical development companies.

Analysis Shows Differences in COVID-19 Vaccine Trial Recruitment

	The impact of COVID-19 continues to be enormous; since the onset, billions of people have experienced some form of ‘lockdown’. With countries now starting to ease shelter-in-place conditions, the thoughts of many are slowly turning to getting back to ‘normal’, however long away that might be. The field of clinical trials is no exception and finds itself at a potential turning point. Although current circumstances are challenging, there is also now an opportunity, when ‘normal’ service resumes, to make long-lasting changes that benefit biopharmaceutical companies and trial sponsors, but most importantly, benefit patients. One of the key determinants in doing this will be an improved use of data, and the current hiatus is an opportunity to embrace this approach.

	Trial infrastructure has been hit hard by COVID-19; recent data from Phesi analyzing more than 300,000 global sites found a 38% increase in suspensions since the beginning of the year (Figure 1). The initial conclusions seem obvious-different trials for different indications, started at different times, sponsored by different companies, all put on hold as the pandemic began. But it is not quite this straightforward, nor is it entirely the fault of COVID-19. Undoubtedly, many trials have been suspended because of the pandemic, but there are some other longer-standing issues currently being masked by the virus. 

	One of these issues is that many trials are poorly designed from the outset so their execution is intrinsically flawed-and would be highly likely to fail or require rescue, even if COVID-19 had never happened. Our experience shows us that poorly executed site activation is one of the main drivers of slow patient enrollment behind the downward curve in trial activity, but this is currently being apportioned solely to the impact of COVID-19. 

	A second issue is competition between studies and sites; this has a significant impact on patient enrollment and now in many cases will be disguised as an outcome of COVID-19. Figure 2 highlights this problem; the number of recruiting sites in Crohn’s disease increased in the three years before COVID-19 from under 2,000 to more than 9,000-despite a limited patient population. The challenge is compounded by poor country allocation and investigator site selection, not by the pandemic. The reality is that at a future point, some of these programs will inevitably have to be terminated so the focus can be placed on those with the best chance of succeeding.  

	The issue then becomes deciding which sites should be terminated. And without a deep understanding of the data, it may be those chosen to restart will be the programs most likely to fail, rather than those with a higher probability of reaching patients and enhancing treatments. Indiscriminately suspending all trials then bringing them back to life without a true understanding of what might work, inevitably means some of the ‘zombie’ trials that are prone to failure will be resurrected. 

	Site (re)activation costs $30,000 at a conservative estimate and takes around 100 days. Data and tools exist that can improve the planning and execution of site activation-for example, helping to identify high-performing investigator sites or finding the most relevant CRO with a performance record in the indication under study. Sponsors must tap into this knowledge to be able to bring down site activation time and cost and minimize the risk that a trial will be unsuccessful or require a later rescue.

	We knowthat even without COVID-19, around 1/5 of trials fail, so the key to overcoming these hurdles is using data to optimize trial design and execution. This enables sponsors to identify all the variables associated with their study; analysis of the clinical site space for a therapeutic area-including geographical location, existing studies, and patient population-builds better protocols with a higher chance of success. 

	In addition, almost all Phase II and III trials will undergo one or more protocol amendments at some point, so it would be wise for sponsors to take advantage of the current slowdown to refine the design now using available data. It’s also likely that given the reduced level of in-person contact caused by social distancing, synthetic control arms will go from being a ‘fashionable’ term pre-COVID-19, to a fundamental part of any successful clinical development portfolio post-COVID-19, as the reliance on analytics and data (including real world data) grows. 

	The COVID-19 pandemic has caused significant global disruption, bringing the industry to a turning point by highlighting the existing issues with trial design and execution. The industry needs to address these problems now to ensure a long-lasting, positive impact on drug development and commercialization. Those companies who make the switch to become data-driven will better navigate the challenges ahead and will ultimately emerge stronger.

With the COVID-19 pandemic highlighting the existing issues with trial design and execution, the industry needs to address these problems now by becoming data-driven to ensure a long-lasting, positive impact on drug development and commercialization. 

Resurrecting Zombie Trials Will Be Another Consequence of COVID-19 Unless the Industry Acts Now

Planning clinical trials is challenging. A significant portion of clinical trials cost more than $100 million each and last several years. By any standard, this is a major capital investment, requiring extensive planning. The complexity of conducting a clinical study is not only reflected by a huge number of variables from the operations management point of view, but also the fundamental reality that clinical trials are medical and scientific experiments. The questions for a clinical trial planner to answer are often in conjunction with those in operations management and medical development.

	While clinical trial planning has been a weak spot for our industry, it is encouraging that many leaders have recognized the importance of planning properly, evidenced by the creation of dedicated clinical trial planning groups, often known as feasibility groups. However, there has been limited progress: delays are still a chronic symptom, costs are ballooning, and rescue missions are a regular part of the trial process. The challenges facing clinical trial planners remain the lack of data and, more importantly, the lack of a platform to interpret the data.

	We recognized that there was no easy fix to these challenges. Over the past 10 years, along with building an extensive and dynamic clinical development database, a set of innovative and coherent concepts has been created to help us to interpret the data, to enable us to effectively plan clinical trials.

	In this article, we use a hematology clinical trial as an example to illustrate how the PhESi clinical trial planning platform was utilized to aid the clinical trial team and facilitate the communication between the team and key stakeholders, namely the senior management.

	The study team faced a familiar scenario: a promising drug candidate, high expectations, demanding timelines, and limited indication experience. This hematological clinical trial would be the first, large-scale, randomized clinical trial for this indication.

	The PhESi platform takes an integrated approach in clinical trial planning. We assess the competitor landscape, including where and when the planned clinical trial will be conducted. Business processes, especially site activation processes,

 are examined in multiple dimensions. Trial design, specifically patient inclusion/exclusion criteria, is comparatively analyzed against similar trials conducted by the industry, by focusing on how these design elements can potentially impact planning parameters and operational deliverables. Last but not least, all the participating investigator sites in relevant clinical trials are assessed by going through a series of proprietary algorithms and statistical models.

 Those that pass this vigorous selection process are provided to the team as site candidates for the trial being planned.

	It is important to emphasize that while our analysis is structured and systematic, not all the detailed results are presented to the team. We focus on providing a set of actionable recommendations the team can act on, substantiated by our analysis, and specific to the particular clinical trial being planned.

	Briefly, the team was asked to conduct a hematology clinical trial, targeting enrollment of 292 patients. The sponsor was hoping to complete enrollment in 22 months.

	There was a limited number of randomized clinical trials similar to our hematology trial. Simply using historical data for our planning was not possible. Extensive historical clinical trial data analysis has revealed that there is a reliable pattern between number of investigator sites (N) being deployed in a clinical trial, and gross site enrollment rate (GSER, defined as the number of patients per site per month). That pattern, with minor modification, can be established for trials in this hematology indication:

	Clearly, for a trial that planned to use over 100 sites, it was not realistic to expect an enrollment rate of more than 0.11 patients per site per month. However, as a mathematical relationship can tell us, the GSER could drop below 0.10 patients per site per month, though not significantly.

	The below chart summarizes the distribution of site size for clinical trials in this hematology indication completed in the past 10 years or so, as measured by the number of patients per site. It is clear that most of the hematology clinical trial sites enrolled 1-3 patients on average.

	The median number of patients per site for trials is 3.0. Knowing that enrollment rate decreases as the number of sites increases, we need to add more sites than the median number of patients per site implies, which requires about 100 sites to enroll 292 patients. Considering these factors, we recommended that the team should use 120 sites, with expected enrollment of 2.4 patients per site.

	One question commonly asked is whether we can proportionally reduce enrollment cycle time by proportionally adding more sites to the mix? The simple answer is no. Among many other reasons, there are operational boundaries in terms of how many sites we can activate that would contribute to enrollment. For a randomized interventional trial targeted to enroll a defined number of patients, we can expect to see an initial shortening of enrollment cycle time when adding sites. As we continue to add more sites, the benefit decreases, eventually resulting in prolonged enrollment cycle time when an excessive number of sites were added to the mix.

 Empirically, we can consistently identify the optimized area (sweet spot), where an adequate number of investigator sites can help us to achieve the shortest enrollment cycle time.

	In planning our trial here, we had to define the optimized number of sites with similar logic, since we could not calculate that “sweet spot” empirically without sufficient historical data.

	Now let us focus on site activation. We examined over 1,000 interventional clinical trials conducted by the sponsor of our trial with 10 or more active sites. We found that only 6% of these studies were able to activate 50 or more sites 100 days after the start date. When we focus on the trials required to activate more than 50 sites, 20% of the trials were able to activate more than 50 sites in the first 100 days. As depicted in the following chart, even if we put more resources into the larger trials that require a larger number of the sites to be activated, the percentage of trials that can activate 50 or more sites in 100 days plateaued at 25% to 27%:

	In other words, only a small percentage (~25%) of large-scale trials can activate 50 sites in 100 days-it is, therefore, an overly ambitious performance goal.

	Is it feasible to enroll 292 patients in 22 months, when using 120 sites?

	We learned from historical sponsor and industry data that it would take an extraordinary effort to activate 50 sites in the first 100 days. From our analysis, it usually took even longer to activate the next 50 sites. If everything played out to our favor, we would be able to activate 120 sites in nine months (270 days). In those nine months, we could expect to have 60 sites open and enrolling patients on average (assuming a straight site activation curve between month one and month nine). We only had 13 months to fully utilize the enrollment capacity from all the 120 activated sites. In summary, we would only be able to utilize 80% of enrollment capacity from the 120 sites deployed [(50% x 9 months + 100% x 13 months)/ 22 months]. That 80% is referred to as the Site Effectiveness Index (SEI), which measures the success of the site activation process.

	This required us to enroll 0.138 patients per site per month. This enrollment rate was still 26% higher than the historical enrollment rate of these much smaller hematology clinical trials [(0.138/0.11-1)]. Neither an SEI of 80%, nor an adjusted site enrollment rate (ASER) of 0.138 patients per site per month was obtainable.

	ASER, which is the GSER when we assume all the sites can be activated in day 1 of the trial. Mathematically, GSER equals to ASER times SEI. For a given protocol, ASER can be improved through a better site selection process.

	In order to help us to define a more realistic SEI, we examined the site activation curve of a trial with a similar indication from the same sponsor:

	In this trial, the site activation index was 60%. This is one of the best executed site activations by this sponsor in the same therapeutic area. For an ASER of 0.11 patients per site per month, GSER is 0.067 patients per site per month (0.11x60%=0.067). This led us to recommend that the sponsor should use 120 sites to enroll 292 patients, and we forecast an enrollment cycle time of 36 months (292/(120x0.066)), instead of 22 months.

	The enrollment was carried out from the beginning of August 2012 to the end of March 2015, a total of 32 months. The following chart shows the actual site activation curve:

	This chart helps to visualize some of the issues in the implementation of this trial. Thirty percent of sites were activated in the last six months of the enrollment period. For that reason, the enrollment contribution from those 77 sites was very limited, leading to the majority of those sites being nonperforming sites.

	While we recommended using 120 sites for the trial, the team actually activated 227 sites instead. However, when we examine the results closely, there were only about 140 sites that contributed patients, much closer to the number of sites that we suggested. From PhESi internal analysis, it is consistent that the nonperforming sites increase proportionally when more than the optimized number of sites are used.

	The SEI for the site activation process was 44%, lower than the 60% SEI value that we recommended.

	The forecasted GSER was 0.067 patients per site per month. The actual GSER, calibrating the impact from the 77 sites, was 0.061 patients per site per month.

	Ironically, we recommended multiple batches of site activation in our plan:

Only activate 70% of the sites in the first batch. This is based on a limited number of experienced sites in clinical trials in this hematology indication and draining energy during a long enrollment period. At six months, we can activate the remaining 30% of PhESi-recommended sites, as they are identified as top enrollers in the next six months (post FSI). This is the choice between 30% of the second-class sites with six months-longer enrollment time, or 30% of top-rated sites with six months-shorter enrollment time.

	The implementation of a two-batch site activation would have allowed us to more accurately define the number of sites required in the second batch-and when the second batch of sites should be deployed based on the site performance of the first batch of sites. This would maximize the benefit of shortening enrollment cycle time. Taking this approach, it would have been entirely possible to have achieved a 32-month enrollment cycle time by using 120 sites, as we had recommended.

	Traditionally, we measure patient enrollment by the number of subjects enrolled per site per month, which we call the enrollment rate. This measure implies that patient enrollment is basically a site performance issue. In other words, defining site enrollment performance with a metric that is focused on the site enrollment rate suggests that the way to improve recruitment cycle times is by focusing on getting the best possible sites and site-level enrollment enhancement initiatives. Some sponsors formulate their business processes based on this assumption. Not surprisingly, these organizations often run into costly situations when targeted enrollment timelines are delayed.

	In this case study, as in any others that we have worked on, it has been demonstrated that site activation is an important driver in determining enrollment cycle time.

 There are operational limitations on the number of sites that can be activated in a defined time period, which restricts the total number of patients that can be enrolled.

	Another area of limitation is the question of how many sites can and should be deployed in a trial. The dominant thinking in our industry is still misguided on this point. Sponsors believe that if more sites are added to a trial, they will be able to proportionally reduce enrollment cycle time. The obvious fallacies for this thinking is that it implies that if we can add an infinite number of sites to a trial, then we can reduce the enrollment cycle time to near zero!

	In our analysis, for clinical trials in any extensively studied disease indications, enrollment cycle time can always be minimized (the “sweet spot”) by deploying the adequate number of sites (PhESi internal analysis):

	When we step too far out of the sweet spot, (for example, extrapolating the enrollment rate from a Phase II trial to a Phase III trial in the same development program) we can end up in a rescue situation (PhESi internal analysis):

	Objective feasibility gained from our analysis in this cancer trial also allowed the sponsor to improve its relationship with its contract research organization (CRO) partner. By incorporating improvement actions recommended by PhESi, the trial completed in the time frame we recommended.

	Fortunately, the problems described in this article were identified in the planning phase, which allowed the sponsor to avoid potential conflict among key stakeholders, and prevented another possible rescue mission from being required.

	Retrospectively, our plan was not perfect. We should have explicitly spelled out the nonperforming site issue. If we had incorporated nonperforming sites, we could have recommended to the team to deploy 150 sites, expecting 120 sites to enroll one or more patients. Having learned from this experience, nonperforming site analysis is now a regular component of our analysis.

, PhD, Senior Director, Clinical Operations, 

, PhD, Founder and CEO, PhESi, email: gen.li@phesi.com

Acknowledgement: Valerie Legagneur and Karen Correa were formerly employees of Pfizer, Inc. 

	1. Gen Li, 2015, Forecast Enrollment Rate in Clinical Trials. 

	2. Gen Li, 2009. Finding the Sweet Spot. 

. Published October 2, 2009. Available at: 

http://www.pharmexec.com/finding-sweet-spot?id=&pageID=1&sk=&date=

	3. Gen Li, 2008. Site Activation: The Key to More Efficient Clinical Trials. 

. Published December 12, 2008. Available at: h

ttp://www.pharmexec.com/site-activation-key-more-efficient-clinical-trials

	4. Gen Li, 2009. SITE EFFECTIVENESS INDEX AND METHODS TO MEASURE AND IMPROVE OPERATIONAL EFFECTIVENESS IN CLINICAL TRIAL EXECUTION. U.S. patent publication No. 2010-0250273

	5. Gen Li, 2014, METHODS OF FORECASTING ENROLLMENT RATE IN CLINICAL TRIALS, U.S. Serial No. 14/818,438, filed August 5, 2015, which claims the benefit of U.S. Serial No. 62/033,844 

Case study shows that site activation is a key driver in determining patient enrollment cycle time, which can be minimized by identifying the "sweet spot" of sites to deploy for a clinical trial.  

Enrollment Cycle Times Can and Should Be Optimized

	We recognized that there was no easy fix to these challenges. Over the past 10 years, along with building an extensive and dynamic clinical 

development database, a set of innovative and coherent concepts has been created to help us to interpret the data, to enable us to effectively plan clinical trials.